Ann: AnteoTech Signs Australian Distribution Agreement for EuGeni, page-140

I feel for the man as he was put on the spot quite a bit to explain what is going on with the saliva test.

But my take is, it might not worth while to pursue.
That dents the outlook a bit as it was defined as a deal breaker to have it in ones arsenal and sets us aside from other test producers.


My take is that the distribution might be shifting away from Europe to Asia and Australasia which is coinciding with yesterday's announcements.
There are simply too many tests on the market in the European jurisdictions to make strong inroads into manufacturing.
It certainly did not happen in the UK.
I had assumed that our confidential testing there might result in a manufacturing contract.
That has not eventuated.


Our test will be making its way into current hotspots of the outbreak which is great news.
It goes where it is needed.
It is also our entry level into distributing an entire platform, but revenue expectations will obviously have to be reduced to a degree.

all IMO